Amphastar's Q2 2024 revenue grew 25% YOY to $182.4 million, primarily driven by BAQSIMI and Primatene MIST sales. Find out ...

A turbulent series of events around the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around ...

Though Lilly has been in the spotlight for the success of its GLP-1 drugs, the pharma giant has also been investing in a corporate brand campaign to boost its overall reputation.

A new bombshell has been dropped in the scandal-plagued world of Alzheimer’s disease drug development. | Between the two ...

A mong the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for ...

First the drugs tackled diabetes. Then, with just an injection a week, they took on obesity. Now they are being found to ...

Sandoz, Eli Lilly, Bayer, and Genentech executives tell what strikes them about the 2024 presidential race — and how the ...

Under US law, compounding pharmacies can make and sell patent-protected drugs that are on the FDA's shortages list in limited ...

Calling the decision not to disclose the genetic results “certainly troubling” and “ethically fraught,” George Perry, editor ...

We recently looked at Goldman Sachs’ List Of Stocks That Hedge & Mutual Funds Love & Hate: 28 Stocks On The Mutual and Hedge ...

Eli Lilly's donanemab receives UK approval for mild cognitive impairment and mild dementia due to Alzheimer's disease.

Eli Lilly and Company, Novo Nordisk A/S, Roche Holding Ltd ADR, Structure Therapeutics Inc ADR. Read MarketBeat.com (Leo Miller)'s latest article on Investing.com ...